首页> 美国卫生研究院文献>PLoS Clinical Trials >Whole Exome Sequencing Suggests Much of Non-BRCA1/BRCA2 Familial Breast Cancer Is Due to Moderate and Low Penetrance Susceptibility Alleles
【2h】

Whole Exome Sequencing Suggests Much of Non-BRCA1/BRCA2 Familial Breast Cancer Is Due to Moderate and Low Penetrance Susceptibility Alleles

机译:整个外显子组测序表明,大部分非BRCA1 / BRCA2家族性乳腺癌是由于中等和低渗透性易感性等位基因引起的

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

The identification of the two most prevalent susceptibility genes in breast cancer, BRCA1 and BRCA2, was the beginning of a sustained effort to uncover new genes explaining the missing heritability in this disease. Today, additional high, moderate and low penetrance genes have been identified in breast cancer, such as P53, PTEN, STK11, PALB2 or ATM, globally accounting for around 35 percent of the familial cases. In the present study we used massively parallel sequencing to analyze 7 BRCA1/BRCA2 negative families, each having at least 6 affected women with breast cancer (between 6 and 10) diagnosed under the age of 60 across generations. After extensive filtering, Sanger sequencing validation and co-segregation studies, variants were prioritized through either control-population studies, including up to 750 healthy individuals, or case-control assays comprising approximately 5300 samples. As a result, a known moderate susceptibility indel variant (CHEK2 1100delC) and a catalogue of 11 rare variants presenting signs of association with breast cancer were identified. All the affected genes are involved in important cellular mechanisms like DNA repair, cell proliferation and survival or cell cycle regulation. This study highlights the need to investigate the role of rare variants in familial cancer development by means of novel high throughput analysis strategies optimized for genetically heterogeneous scenarios. Even considering the intrinsic limitations of exome resequencing studies, our findings support the hypothesis that the majority of non-BRCA1/BRCA2 breast cancer families might be explained by the action of moderate and/or low penetrance susceptibility alleles.
机译:乳腺癌中两个最普遍的易感基因,BRCA1和BRCA2的鉴定,是人们持续努力寻找新基因以解释这种疾病所缺乏的遗传力的开端。如今,已在乳腺癌中鉴定出其他高,中,低外显率基因,例如P53,PTEN,STK11,PALB2或ATM,全球约占家族病例的35%。在本研究中,我们使用大规模平行测序分析了7个BRCA1 / BRCA2阴性家族,每个家族至少有6名患乳腺癌的女性(6至10岁)被诊断为60岁以下的几代人。经过广泛的筛选,Sanger测序验证和共分离研究后,通过控制种群研究(包括多达750位健康个体)或包含约5300个样品的病例对照试验来确定变体的优先级。结果,鉴定了已知的中等敏感性插入/缺失变异体(CHEK2 1100delC)和11种稀有变异体的目录,这些变异体与乳腺癌相关。所有受影响的基因都参与重要的细胞机制,例如DNA修复,细胞增殖和存活或细胞周期调节。这项研究强调需要通过针对遗传异质情况进行优化的新型高通量分析策略来研究罕见变异在家族性癌症发展中的作用。即使考虑外显子组重测序研究的固有局限性,我们的发现也支持以下假设:大多数非BRCA1 / BRCA2乳腺癌家族可能由中度和/或低渗透性易感性等位基因的作用所解释。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号